Merrion Pharmaceuticals plc announces commencement of next stage

September 2008

Merrion Pharmaceuticals the TCD based Irish American company has confirmed that it has begun a joint feasibility study on oral drug delivery with Swiss based multinational Ferring Pharmaceuticals.

Merrion was set up by Life sciences venture capital group Growcorp when it acquired a basket of drug delivery technologies from Elan in 2002. It specialises in manufacturing oral versions of previously injectable only medicines.

The joint programme will test the efficiency of Merrion's technology to improve the oral absorption of drugs.

July 2008

Merrion Pharmaceuticals plc announces commencement of next stage of oral drug research collaboration programme with Novo Nordisk

Dublin, Ireland

Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on from the completion of several oral feasibility studies combining Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) oral drug delivery technology with Novo Nordisk compounds. In continuation of this collaboration, Merrion will now complete the development of solid dosage forms with GIPET for additional testing.

²We are very pleased to be working on oral versions of Novo Nordisk¢s compounds. We believe there can be substantial benefit to patients in having oral formulations on these compounds available - and our GIPET technology has shown the ability to significantly improve the oral delivery of these drugs. ²John Lynch, Merrion¢s CEO said to-day.

Merrion was founded Growcorp Group Limited who acquired the Intellectual Property from Elan in 2004 created a business plan and recruited the senior management.

In more than 20 clinical studies, GIPET technology has been shown to improve the oral absorption of a wide range of drugs, by between 500% and 1500%. Drugs studied ranged from small molecules to small proteins. Merrion currently has four products in development, as well as several collaboration agreements with pharmaceutical partners, using this technology.


 
Copyright 2007 Growcorp Group. All Rights Reserved.
Office: Growcorp Group Limited, 3015 Lake Drive, Citywest Campus, Citywest, Dublin 24 | Telephone: +353 1 4661000 | Fax: +353 1 4661002
2008
Galway and Dublin. Wednesday, 3rd December, 2008: Growcorp Group, the Irish investment vehicle, will earn over Eur 7m following the acquisition this week of Irish theranoistic company Neutekbio by Danish biotechnology development company Merrion Pharmaceuticals has signed a multi-million euro deal with Novo Nordisk to develop oral diabetes products.

2008
DUBLIN, Ireland, Nov 5, 2008 an international specialty pharmaceutical company, today announced that it has been awarded the Frost & Sullivan 2008 Osteoporosis Technology Innovation of the Year Award

2008
DUBLIN, Ireland, Nov 5, 2008 an international specialty pharmaceutical company, today announced that it has been awarded the Frost & Sullivan 2008 Osteoporosis Technology Innovation of the Year Award

2008
Merrion Pharmaceuticals the TCD based Irish American company has confirmed that it has begun a joint feasibility study on oral drug delivery with Swiss based multinational Ferring Pharmaceuticals.

2007
Merrion Pharmaceuticals Plc was admitted to the IEX today and commenced
unconditional trading.........

2006
Merrion Pharmaceuticals Ltd, Dublin, announced the successful......        

Enterprise START Programme As Enterprise Ireland are anxious to..........

Merrion Pharma raises Eur 5M ahead of 2007 float Dublin drugmaker..........

Pharma Firm Merrion Hires Funding Adviser Merrion Pharmaceuticals.........

2004
Maher appointed MD at bioscience investment specialist Growcorp.........

Biopharma Firm Plans Drug Launch.........

Investing in Ireland From World Pharmaceutical Frontiers..........